Zewei Shen

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China.

Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China.

Journal: Cardiology and therapy

Published: May 13, 2026

Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.

Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: December 19, 2025

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: December 09, 2025

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.

Journal: Diabetes, obesity & metabolism

Published: May 05, 2025

Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.

Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.

Journal: Diabetes, obesity & metabolism

Published: March 04, 2025

Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Journal: Diabetes, obesity & metabolism

Published: October 31, 2024

Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.

Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.

Journal: Diabetes, obesity & metabolism

Published: May 13, 2024

Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.

Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.

Journal: Diabetes, obesity & metabolism

Published: April 16, 2024

Perceptions, attitudes and barriers to effective obesity care among people living with obesity and healthcare professionals in China: The ACTION-China study.

Perceptions, attitudes and barriers to effective obesity care among people living with obesity and healthcare professionals in China: The ACTION-China study.

Journal: Diabetes, obesity & metabolism

Published: April 12, 2024

Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults.

Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults.

Journal: Diabetes, obesity & metabolism

Published: March 28, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026